.svg){kind=small}
71 participants from 12 countries helped make this international workshop focused on bridging strategies from early development to regulatory approval a resounding success. The workshop featured an outstanding speaker panel of experts from industry, academics and the MHRA.Many of the current issues and challenges in the development of both innovative and generic topically applied drug products were addressed.Watch our latest video on our experience in dermatology studies
.avif)
Latest news
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
